Navigation Links
Tengion Announces FDA Orphan-Drug Designation for Neo-Urinary Conduit
Date:6/9/2011

al candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.

Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans to develop and commercialize its product candidates, including the Neo-Urinary Conduit and the Neo-Kidney Augment; (ii) expectations regarding the initial clinical trial of the Neo-Urinary Conduit and (iii) expectations regarding planned preclinical studies of the Neo-Kidney Augment. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company's Neo-Urinary Conduit clinical trial will not be placed on clinical hold by the Food and Drug Administration, or FDA; (ii) patients enrolled in the Company's Neo-Urinary Conduit clinical trial will not experience additional adverse events, which could delay clinical trials or cause the Company to terminate the development of the Neo-Urinary Conduit; (iii) the Company will be able to successfully enroll patients in its clinical trials, including its initial clinical trial for the Neo-Urinary Conduit; (iv) the results of the clinical trial for the Neo-Urinary Conduit will support further development of that product candidate; (v) data from the Company's ongoing preclinical studies will continue to be supportive of advancing its preclinical product candi
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
2. Tengion Advances Clinical Trial for Neo-Urinary Conduitâ„¢ in Bladder Cancer Patients
3. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
4. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
5. Tengion Announces First Implantation of Neo-Urinary Conduitâ„¢ in Initial Clinical Trial in Patients with Bladder Cancer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
8. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
9. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
10. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... An analysis done by the CVS Health ... a new and expensive treatment for Hepatitis C introduced ... several months (May through August 2014) there has been ... This suggests another surge of patients will begin therapy ... efficacy and shorter duration are introduced in the Fall. ...
(Date:9/17/2014)... Utah , Sept. 17, 2014  NuView ... exclusive global licensing and collaboration agreement with Otsuka ... commercialize NuView,s investigative genomic-based diagnostic biomarker to detect ... also includes all other future diagnostic-imaging applications. NuView ... in-vivo therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... LAWRENCEVILLE, N.J. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... that details how to implement GS1 Standards to ... (DSCSA), and enhance patient safety and security in ... Applying GS1 Standards to U.S. Pharmaceutical Supply ... Chain Security Act , was developed in ...
Breaking Medicine Technology:CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
... - Opexa,Therapeutics, Inc. (NASDAQ:OPXA), a company involved ... today,announced positive top-line data in an open-label ... T-cell vaccine,Tovaxin(TM), for multiple sclerosis (MS). In ... remitting (RRMS),and secondary progressive (SPMS) subjects, Tovaxin ...
... 2007 - “In anaplastic,astrocytoma, AP 12009 as a ... Wong, M.D., Stanford,University, California, U.S.A. commented on the ... 12009, under development,by Antisense Pharma. Prof. Wong discussed ... session on central nervous system tumors,at the 43rd ...
Cached Medicine Technology:Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 2Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 4Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 5Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 2Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 3Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 4
(Date:9/17/2014)... gene manipulation these sound like the ideas ... they are components of an exciting new approach ... animal models of metastatic prostate cancer, scientists at ... of Molecular Medicine and Johns Hopkins Medical Institutions ... approach that could revolutionize doctors, ability to see ...
(Date:9/17/2014)... Tidewater Physical Therapy and ... for football players and their parents at its Newport ... open at 6:30 p.m. for athletes and parents to ... and physical therapists. The workshop will start at 7 ... News Tidewater Performance Center, which features sports performance and ...
(Date:9/17/2014)... adjourns this month for the November elections, one of ... way out the chamber door will be the Sustainable ... Act of 2014. In a new commentary in the ... what he and other advocates saw as the merits ... how Medicare pays doctors will return for the next ...
(Date:9/17/2014)... The Food and Drug Administration (FDA) ... to consider: , 1. The appropriate ... 2. The potential for adverse cardiovascular outcomes ... litigation ongoing, an informally-organized litigation group subcommittee prepared a ... replacement therapy. Among others, ZKB attorney Michelle L. Kranz ...
(Date:9/17/2014)... Leading eco-friendly beauty brand , ... its new vegan and gluten-free Sugar Cane Fruit Mask. ... the results skincare testers were looking for. , ... active mask that provided results, and I think I ... Cane Fruit Mask combines Willow bark (Salix Alba extract), ...
Breaking Medicine News(10 mins):Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2
... , March 11 As reported in today,s ... Americans with atrial fibrillation are now on notice that the over-zealous ... are not approved by the U.S. Food and Drug Administration (FDA) ... doctors, and hospitals, decisions about treatment for their patients, heart conditions. ...
... snorting cocaine among 12-year-olds, study finds , THURSDAY, March ... inhalants to get high than marijuana, cocaine and hallucinogens ... deadly inhalants include aerosol computer cleaners, glue, hair sprays, ... can cause addiction or sudden death from cardiac arrest. ...
... sign, but exercise regimens can help, experts say , THURSDAY, ... researchers report that preseason measurements of rotator cuff strength can ... developing a shoulder injury during play. , "We found certain ... players are more likely to incur injury that requires surgery," ...
... key to more effective treatment for Alzheimer,s disease and other ... test developed at the University of Tennessee is more than ... diseases. The test, called CST -- for computerized self ... simple for medical professionals to administer and for patients to ...
... monkey babies born to mothers who had the flu while ... to those observed in human patients with schizophrenia, a study ... of North Carolina at Chapel Hill has found. The ... is the first study done with monkeys that examines the ...
... Mo. While there are many benefits of losing weight, ... During weight loss, bones are being remodeled - breaking down ... rate. As a result, bone density is reduced, causing increased ... that weight-bearing exercise, in this case, fast walking or jogging, ...
Cached Medicine News:Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 2Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 3Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 4Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 5Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 6Health News:Inhalant Abuse a Deadly Middle-School Concern 2Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 2Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 3Health News:New Alzheimer's test offers better opportunities for early detection 2Health News:Mother's flu during pregnancy may increase baby's risk of schizophrenia 2Health News:Weight-bearing exercise does not prevent increased bone turnover during weight loss 2
... the most powerful isolated ESU on the market ... is the only ESU that allows the surgeon ... with a standard ES pencil. Excalibur Plus PC ... necessary voltage for smooth cutting through various impedance ...
High performance capabilities in a multipurpose generator, blended cut modes, simultaneous independent coagulation, low voltage coagulation, valleylab REM safety substantially reduces the risk of pat...
The Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Lorgnette pinhole occluder...
Medicine Products: